Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pilot study of romiplostim secondary prophylaxis for chemotherapy-induced thrombocytopenia in non-Hodgkin lymphoma
2011-003824-12Phase 2Terminated
- Sponsor
- Fondazione Centro San Raffaele
- Start
- Mar 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romiplostim in chemotherapy-induced thrombocytopenia (CIT) and non-Hodgkin lymphoma (NHL), sponsored by Fondazione Centro San Raffaele. Primary endpoint: Romiplostim safety. Started Mar 2012; status: terminated.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2011-003824-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003824-12.